SYK

Stryker Corporation

$310.00

-0.98%
Nov 20, 2026
Bobby Quantitative Model
Stryker Corporation designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices spanning orthopaedic implants, MedSurg equipment, endoscopy systems, operating room infrastructure, neurovascular products, and orthopedic robotics, operating within the global medical devices industry. The company is one of the three largest competitors in reconstructive orthopaedic implants and holds a leadership position in operating room equipment, giving it a scale-driven, hospital-relationship-anchored competitive identity that blends capital equipment cycles with recurring consumable revenue. The current investor narrative centers on a sharp divergence between Stryker's long-term structural growth story and near-term execution concerns, after the Q3 2026 earnings call highlighted softer demand and a downward revision to full-year 2026 guidance, driving a violent single-day repricing in early September and leaving the stock down materially over the trailing year even as the broader market rallied. Offsetting this, the company continues to bolt on tuck-in M&A such as the completed acquisition of Amplitude Vascular Systems to add next-generation intravascular lithotripsy technology to its peripheral vascular portfolio, and the stock has staged a sharp November rebound following the late-October print, keeping the debate focused on whether procedure volumes and margin recovery can reaccelerate into 2027.

People also watch

Abbott Laboratories

Abbott Laboratories

ABT

Analysis
Medtronic plc

Medtronic plc

MDT

Analysis
Boston Scientific

Boston Scientific

BSX

Analysis
Edwards Lifesciences

Edwards Lifesciences

EW

Analysis
GE HealthCare

GE HealthCare

GEHC

Analysis

BobbyInvestment Opinion: Should I buy SYK Today?

Rating: Hold with a constructive bias. The core thesis is that Stryker's de-rating has largely run its course — the forward PE of 19.01x on consensus EPS of $21.65 sits near the bottom of the company's own 34.9x-62.9x trailing band — but the fundamental inflection (margin recovery and reaccelerating procedure volumes) has not yet been demonstrated, so the 9.6% implied upside to the $339.37 average target does not yet justify aggressive accumulation. The 22-Buy/8-Hold/0-Sell consensus with a 1.8 recommendation mean anchors the view that the franchise is intact, while the absence of any downgrade after the Q3 miss supports treating the selloff as a valuation reset rather than a thesis break.

The supporting evidence is a genuine tug-of-war. On the positive side: revenue still grew 7.64% YoY to $6.52 billion in Q3 2026, trailing free cash flow of $4.573 billion yields roughly 3.4% on the $134.3 billion market cap, and the balance sheet is fortress-grade (debt-to-equity 0.73, current ratio 1.89, $3.271 billion cash). On the negative side: Q3 operating margin of 15.86% collapsed from Q2's 25.18%, net margin fell to 11.55% from 19.37%, the PEG ratio of 5.16 and 23.23x EV/EBITDA flag a premium that is hard to defend at a 7.64% growth rate, and the stock has lagged SPY by 29.35 percentage points over the trailing year. The forward multiple near 19x versus a historical trailing band of 35-63x is the crux: it either prices in a recovery that is coming, or it is a value trap if 2027 guidance disappoints.

The biggest risks that could invalidate the thesis are (1) Q4 2026 confirming continued procedure-volume softness and 2027 guidance landing below the $35.32 billion revenue / $21.65 EPS consensus, (2) further margin compression that forces analysts to capitulate on the 22-Buy consensus, and (3) a break below the $267 52-week low that opens a new leg toward the mid-$250s. This Hold would upgrade to Buy if Q4 operating margin recovers above 20% and 2027 guidance re-establishes high-single-digit growth, or if the forward PE compresses below 17x on stable estimates; it would downgrade to Sell if revenue growth decelerates below 5% or the $267 support fails on volume. Valuation verdict: fairly valued to modestly undervalued relative to Stryker's own history, but still at a premium to the broad medical devices sector on PS (5.35x) and EV/EBITDA (23.23x) — a stock priced for a recovery it has yet to prove.

Sign up to view all

SYK 12-Month Price Forecast

The forward-looking view is genuinely balanced: the valuation reset to 19x forward earnings has removed most of the multiple risk, but the fundamental evidence — a 7.64% growth rate that plateaued sequentially and a ~930bps operating-margin compression in Q3 — has not yet turned. The sell-side is defending the franchise (22 Buys, zero Sells, no post-miss downgrades), which supports a base case of sideways-to-modestly-higher performance toward the $339 average target, but the stock's failure to hold its November spike above $339.65 shows the market wants proof before paying up. The single variable that most changes the thesis is Q4 margin and 2027 guidance: a clean margin recovery above 20% with high-single-digit 2027 growth would justify upgrading to bullish and targeting the $389-410 range, while a second consecutive guidance cut would validate the bear case toward $267-275. With a beta of 0.774 limiting downside participation and a 0.96% dividend yield providing a modest income floor, the risk/reward skews modestly positive but lacks a near-term catalyst strong enough to justify a high-conviction bullish stance.

Historical Price
Current Price $310.00
Average Target $341.13
High Target $410.00
Low Target $267.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $341.48 and implied upside of +10.2% versus the current price.

Average Target

$341.48

30 analysts

Implied Upside

+10.2%

vs. current price

Analyst Count

30

covering this stock

Price Range

$275 - $410

Analyst target range

Buy
22 (73%)
Hold
8 (27%)
Sell
0 (0%)

Coverage is broad and overwhelmingly constructive: 27 analysts cover Stryker with a distribution of 22 Buy, 8 Hold, and 0 Sell, yielding a consensus recommendation of "buy" and a recommendation mean of 1.8 (where 1.0 is a strong buy). The average target price of $339.37 implies roughly 9.6% upside from the current $309.64, a moderate rather than aggressive expected return that reflects the recent guidance cut. Consensus estimates call for EPS averaging $21.65 (range $21.36 to $22.51) on average revenue of $35.32 billion (range $34.96 billion to $36.40 billion), and the tightness of the EPS estimate band — a spread of only about 5% — signals high confidence in near-term earnings even as the stock price has been volatile. The consensus leans bullish on ratings but only modestly so on price, a combination consistent with analysts defending the long-term franchise while acknowledging near-term headwinds. The target range of $275.00 to $410.00 is wide, spanning a -11.2% downside to a +32.4% upside from the current price, which signals meaningful disagreement about the recovery path. The $410 high target likely assumes multiple re-expansion back toward historical norms alongside reaccelerating procedure volumes and margin recovery into 2027, while the $275 low target — essentially at the 52-week low of $267 — prices in continued demand softness, further guidance cuts, and margin compression. Institutional ratings show a stable-to-supportive pattern with no downgrades in the recent tape: Piper Sandler reiterated Overweight on November 9, Stifel reiterated Buy on November 2, and the late-October post-earnings wave saw JP Morgan, Citigroup, Needham, BTIG, RBC, and Barclays all maintain Buy/Overweight/Outperform ratings, with only Truist and TD Cowen holding at Hold. The absence of any downgrade despite the Q3 miss and lowered guidance suggests the sell-side views the pullback as a valuation reset rather than a thesis break, though the wide target spread and the stock's failure to hold its November spike indicate the market is not yet fully convinced.

Drowning in data?

Find the real signal!

Bulls vs Bears: SYK Investment Factors

The bear case currently holds the stronger near-term evidence: revenue growth has decelerated to 7.64% with a sequential plateau, Q3 margins compressed sharply (operating margin 15.86% vs. Q2's 25.18%), guidance was cut, and the stock has underperformed SPY by 29.35 percentage points over the trailing year. The bull case rests on valuation and franchise quality — a 19.01x forward PE near the bottom of Stryker's historical 34.9x-62.9x band, a fortress balance sheet with $4.573 billion of trailing FCF, and a 22-Buy/0-Sell analyst consensus with a $339.37 average target. The single most important tension is whether procedure volumes and margin recovery reaccelerate into 2027: if Q4 margins stabilize and 2027 guidance re-establishes high-single-digit growth, the 19x forward multiple re-rates toward the mid-20s and the $339-352 resistance breaks; if demand softness persists and margins compress further, the $267 low comes back into play. On balance the evidence favors a neutral-to-modestly-constructive stance — the de-rating has largely happened, but the fundamental inflection has not yet been demonstrated.

Bullish

  • Forward PE of 19x is cheap for franchise: The trailing PE of 41.40x collapses to a forward PE of 19.01x on consensus EPS of $21.65, a ~54% compression that prices in substantial execution risk. For a company still growing revenue 7.64% YoY with a 63.96% trailing gross margin, a high-teens forward multiple sits near the low end of Stryker's own historical band (trailing PE ranged 34.9x-62.9x from Q4 2024 to Q3 2026).
  • Analyst consensus firmly Buy, no sells: Of 27 covering analysts, 22 rate Buy, 8 Hold, and 0 Sell, with a recommendation mean of 1.8 and an average target of $339.37 implying 9.6% upside from $309.64. Critically, JP Morgan, Citigroup, Needham, BTIG, RBC, Barclays, Piper Sandler, and Stifel all reiterated Buy/Overweight/Outperform after the Q3 miss, signaling the sell-side views the drop as a valuation reset rather than a thesis break.
  • Balance sheet and FCF fund the story: Debt-to-equity of 0.73, a current ratio of 1.89, and $3.271 billion of cash underpin a fortress balance sheet, while trailing free cash flow of $4.573 billion yields roughly 3.4% on the $134.3 billion market cap. Q3 operating cash flow of $1.461 billion against only $237 million of capex shows the business self-funds tuck-in M&A like the Amplitude Vascular Systems IVL deal without strain.
  • Full correction already occurred: The stock's maximum drawdown of -30.54% and its position at $309.64 — roughly 34.6% up the 52-week range of $267.00 to $389.33 — indicate distribution is largely done rather than beginning. The one-month gain of 9.95% versus SPY's -2.26% (relative strength +12.21) shows buyers stepping in around the $270-275 base that held through September and October.

Bearish

  • Growth decelerating and guidance cut: Q3 2026 revenue of $6.52 billion grew only 7.64% YoY and actually declined sequentially from Q2's $6.589 billion, a plateau rather than acceleration. The Q3 call explicitly cited softer demand and a downward revision to full-year 2026 guidance, the proximate cause of the violent early-September repricing.
  • Margin compression over two quarters: Q3 gross margin of 65.15% and net margin of 11.55% compare unfavorably to Q2's 68.27% and 19.37%, while Q3 operating margin of 15.86% fell well below Q2's 25.18%. The Q3 effective tax rate of 24.47% versus Q2's 18.41% compounded the bottom-line hit, and the trajectory is compressing rather than expanding.
  • PEG of 5.16 flags premium per growth: At 5.35x sales, 4.94x EV/Sales, 23.23x EV/EBITDA, and 5.99x book, Stryker trades at a premium to the broad medical devices sector, and the PEG ratio of 5.16 is the clearest red flag that investors pay a steep price per unit of expected growth. The premium is defensible on franchise quality but hard to justify at a 7.64% growth rate.
  • Severe relative underperformance: The stock is down 17.08% over the trailing year versus SPY's +12.27%, a relative strength gap of -29.35 percentage points, and remains down 8.72% over three months and 11.07% YTD. The defensive beta of 0.774 did not protect shareholders during this idiosyncratic de-rating, and the November spike from $310.55 to $339.65 has already given back ~8.8% to $309.64.

SYK Technical Analysis

Stryker is in a damaged but stabilizing downtrend: the stock is down 17.08% over the trailing year versus a 12.27% gain for SPY, a relative strength gap of -29.35 percentage points, and sits at 309.64, which is roughly 34.6% of the way up its 52-week range of 267.00 to 389.33. That positioning near the lower third of the annual band signals the stock has absorbed significant distribution rather than trading at momentum highs, though the fact it is holding well above the 267.00 low argues against an outright falling-knife characterization. The maximum drawdown of -30.54% confirms a full correction has already occurred, meaning the risk/reward skew has shifted from trend-following short to mean-reversion watch. Recent momentum is sharply bifurcated: the stock has gained 9.95% over the past month, dramatically outperforming SPY's -2.26% for a relative strength reading of +12.21, yet it remains down 8.72% over three months and 11.07% year-to-date. This one-month surge against a negative one-year trend is a classic counter-trend rally, likely catalyzed by the post-earnings relief move visible in the price series, which jumped from 310.55 on November 3 to 339.65 on November 4 before fading back to 309.64 by November 13 — a give-back of roughly 8.8% from that spike high that suggests the rally is encountering supply rather than confirming a durable reversal. Key levels are well defined: support sits at the 267.00 52-week low, with secondary support around the 269.75-275.00 zone that contained the September-October basing effort, while resistance lies at the 339.65-352.25 area where the July and November rallies both failed, with the 389.33 high as the longer-term ceiling. A decisive close above 352 would break the pattern of lower highs and signal trend repair, whereas a break of 267 would open a new leg lower and invalidate the base; with a beta of 0.774, Stryker is roughly 23% less volatile than the market, meaning position sizing can tolerate a larger notional exposure for equivalent risk budget, but the defensive beta has not protected shareholders during this idiosyncratic de-rating.

Beta

0.77

0.77x market volatility

Max Drawdown

-30.5%

Largest decline past year

52-Week Range

$267-$389

Price range past year

Annual Return

-14.0%

Cumulative gain past year

PeriodSYK ReturnS&P 500
1m+4.2%-9.7%
3m-5.9%-9.9%
6m-2.0%-7.5%
1y-14.0%+4.7%
ytd-11.0%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

SYK Fundamental Analysis

Revenue is growing at a healthy but moderating pace: Q3 2026 revenue of $6.52 billion represents 7.64% year-over-year growth against $6.057 billion in Q3 2025, and the sequential trajectory ($6.02B in Q1, $6.589B in Q2, $6.52B in Q3) shows a plateau rather than acceleration into the back half. Segment mix is balanced, with MedSurg at $3.664 billion and Orthopaedics at $2.856 billion, meaning the capital-equipment-levered MedSurg franchise is the larger growth engine and the one most exposed to the softer hospital demand cited on the Q3 call. The 7.64% growth rate is respectable for a large-cap device maker but represents a deceleration that, combined with the lowered 2026 outlook, explains why the market has re-rated the shares despite the top line still expanding. Profitability is solid but showed notable quarterly volatility: Q3 2026 net income of $753 million on a 65.15% gross margin and 11.55% net margin compares unfavorably to Q2's $1.276 billion net income, 68.27% gross margin, and 19.37% net margin, a compression that likely reflects one-time charges and mix. Operating margin of 19.47% (TTM basis) and Q3 operating income of $1.034 billion (15.86% operating margin) sit below the 25.18% operating margin posted in Q2, and the Q3 effective tax rate of 24.47% versus Q2's 18.41% further weighed on the bottom line. Against a 63.96% trailing gross margin and 12.92% net margin, Stryker remains a high-quality, structurally profitable franchise, but the margin trajectory over the last two quarters is compressing rather than expanding, which is the core fundamental risk the market is pricing. The balance sheet is sound: debt-to-equity of 0.73, a current ratio of 1.89, and $3.271 billion in cash at Q3 end provide ample liquidity, while trailing free cash flow of $4.573 billion against a $134.3 billion market cap implies an FCF yield of roughly 3.4%. Quarterly FCF has been uneven ($1.224B in Q3, $1.059B in Q2, $415M in Q1) due to working capital swings and $1.0 billion of Q3 share repurchases, but the business clearly funds itself internally, with capex of only $237 million in Q3 against $1.461 billion of operating cash flow. ROE of 14.48% and ROA of 8.36% are respectable though not exceptional for the sector, and the 0.73 leverage ratio leaves room for continued tuck-in M&A without balance-sheet strain.

Quarterly Revenue

$6.5B

2026-09

Revenue YoY Growth

+7.6%

YoY Comparison

Gross Margin

65.1%

Latest Quarter

Free Cash Flow

$4.6B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

MedSurg
Orthopaedics

Open an Account, get $2 TSLA now!

Valuation Analysis: Is SYK Overvalued?

Because Stryker is solidly profitable (Q3 net income of $753 million; TTM net margin 12.92%), the PE ratio is the appropriate primary metric, and the dispersion between trailing and forward multiples is the key signal: the trailing PE of 41.40x collapses to a forward PE of 19.01x, a roughly 54% compression that implies the market expects a substantial earnings step-up. That gap is partly an artifact of the depressed trailing figure — the reported EPS of $0.024 in the key metrics data appears distorted by charges — but the forward multiple near 19x on estimated EPS of $21.65 is genuinely modest for a franchise of this quality, suggesting the market is discounting meaningful execution risk rather than paying for growth. On peer comparison, the 5.35x PS ratio and 4.94x EV/Sales sit at a premium to the broad medical devices sector, while the 23.23x EV/EBITDA is elevated relative to typical large-cap medtech levels in the high teens, and the 5.99x P/B reflects a rich asset multiple; the PEG ratio of 5.16 is the clearest red flag, indicating investors are paying a steep price per unit of expected growth. The premium is defensible on franchise quality and recurring revenue but hard to justify at current growth rates, which is precisely why the stock has de-rated. Historically, Stryker's PE has ranged widely — 62.9x in Q4 2024, 54.4x in Q1 2025, 42.6x in Q2 2025, and 34.9x in Q3 2026 — showing a clear multi-quarter compression toward the bottom of its own band, while the PS ratio has fallen from 25.1x in Q2 2025 to 16.1x in Q3 2026 and the P/B from 7.14x to 4.49x. This places the stock near the low end of its historical valuation range, which could represent a value opportunity if margins and growth stabilize, or a warning that the market expects further fundamental deterioration; the forward PE near 19x versus a historical trailing band of 35-63x suggests investors are being asked to underwrite a recovery that has not yet been evidenced in the numbers.

PE

41.4x

Latest Quarter

vs. Historical

High-End

5-Year PE Range 29x~46x

vs. Industry Avg

26.4x

Industry PE ~26.4x*

EV/EBITDA

23.2x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on margin volatility and growth dependence. Q3 2026 operating margin of 15.86% fell roughly 930 basis points from Q2's 25.18%, and net margin dropped from 19.37% to 11.55%, showing how quickly profitability can swing on mix and one-time charges; the Q3 effective tax rate of 24.47% versus Q2's 18.41% amplified the hit. Revenue growth of 7.64% YoY is respectable but decelerating, and the sequential plateau ($6.02B Q1, $6.589B Q2, $6.52B Q3) means the forward PE of 19.01x requires an earnings step-up to consensus EPS of $21.65 that has not yet been evidenced. Segment concentration adds risk: MedSurg at $3.664 billion is the larger and more capital-equipment-levered franchise, making it the most exposed to the softer hospital demand cited on the Q3 call, while the 0.73 debt-to-equity and $3.271 billion cash position keep balance-sheet risk low but do not offset earnings volatility. Market and competitive risks are dominated by valuation compression and sector rotation. The PEG ratio of 5.16, 23.23x EV/EBITDA, and 5.35x PS all sit at premiums to typical large-cap medtech levels, so any further growth disappointment invites multiple contraction rather than just earnings cuts; the trailing PE has already fallen from 62.9x in Q4 2024 to 34.9x in Q3 2026, and there is no structural floor preventing further de-rating. The beta of 0.774 offers limited macro protection — it did not shield shareholders during a 17.08% trailing-year decline against SPY's +12.27% — and competitive pressure in orthopaedics and peripheral vascular (where the Amplitude IVL acquisition is a response) plus hospital capital-spending caution are live threats. The worst-case scenario is a chain in which Q4 2026 confirms continued procedure-volume softness, 2027 guidance comes in below the consensus $35.32 billion revenue and $21.65 EPS, and analysts capitulate on the 22-Buy consensus, forcing the forward multiple below 19x on lower numbers. In that path the stock retests the $267.00 52-week low — a decline of roughly 13.8% from $309.64 — and a break below it, consistent with the $275 analyst low target and the -30.54% historical max drawdown, would open a new leg toward the mid-$250s, implying losses of roughly 15-20% from current levels.

FAQ

The most severe risk is fundamental: margin compression and decelerating growth. Q3 2026 operating margin of 15.86% fell roughly 930 basis points from Q2's 25.18% and net margin dropped to 11.55% from 19.37%, while revenue growth of 7.64% plateaued sequentially ($6.02B Q1, $6.589B Q2, $6.52B Q3) after a guidance cut — if this persists into 2027 guidance, the 19x forward multiple is built on numbers that get cut. Second is valuation compression risk: at 23.23x EV/EBITDA and a PEG of 5.16, any further disappointment invites multiple contraction on top of earnings cuts, and there is no structural floor preventing further de-rating from the already-compressed 34.9x trailing PE. Third is company-specific execution risk around the MedSurg segment ($3.664 billion, the larger and more capital-equipment-levered franchise) and the Amplitude Vascular Systems IVL integration in peripheral vascular, where competitive pressure is live. Fourth, macro and market risk is real but secondary: the 0.774 beta did not protect shareholders during a 17.08% trailing-year decline versus SPY's +12.27%, a -29.35 percentage point relative strength gap, and hospital capital-spending caution remains a swing factor.

The scenario framework is roughly balanced with a slight base-case tilt: a 50% base case targets $330-$352.25 (sideways-to-higher toward the $339.37 average analyst target, about 9.6% upside), a 25% bull case targets $389.33-$410 (multiple re-rating toward the mid-20s forward PE on margin recovery above 20% and high-single-digit 2027 growth), and a 25% bear case targets $267-$275 (a second guidance cut and analyst capitulation, roughly 11-14% downside). The base case is most likely and rests on the key assumption that Q4 operating margin recovers to the high-teens to ~20% from Q3's 15.86% and that forward PE holds near 19-21x on stable consensus EPS of $21.65. The single variable that most changes the forecast is Q4 margin and 2027 guidance: a clean recovery would shift probability weight toward the bull case, while a second consecutive cut would validate the bear case. Note the analyst target range of $275-$410 spans -11.2% to +32.4%, signaling genuine disagreement about the recovery path.

The answer depends heavily on which multiple you anchor to, and that dispersion is the story. On trailing PE of 41.40x the stock looks expensive, but that figure is distorted by depressed trailing earnings; the forward PE of 19.01x on consensus EPS of $21.65 represents roughly 54% compression and sits near the low end of Stryker's own historical band, which fell from 62.9x in Q4 2024 to 34.9x in Q3 2026. On peer-relative measures the stock still carries a premium: 5.35x PS, 4.94x EV/Sales, 23.23x EV/EBITDA, 5.99x book, and a PEG of 5.16 that flags a steep price per unit of expected growth. The PS ratio has already compressed from 25.1x in Q2 2025 to 16.1x in Q3 2026 and P/B from 7.14x to 4.49x, confirming a multi-quarter de-rating. Net, the stock looks fairly valued to modestly undervalued versus its own history but still at a premium to the broad medical devices sector — the market is pricing in a margin and volume recovery that has not yet been evidenced.

From a risk/reward perspective, SYK offers a moderate rather than compelling setup: the $339.37 average analyst target implies about 9.6% upside from $309.64, while the $275 low target and $267 52-week low imply roughly 11-14% downside, so the skew is only modestly favorable. The valuation support is genuine — a 19.01x forward PE on consensus EPS of $21.65 sits near the bottom of Stryker's own 34.9x-62.9x trailing band — and the 22-Buy/0-Sell consensus with no post-miss downgrades suggests the sell-side views the Q3 selloff as a valuation reset rather than a thesis break. Against that, the fundamental evidence has not turned: revenue growth of 7.64% plateaued sequentially and Q3 operating margin of 15.86% fell roughly 930 basis points from Q2's 25.18%. The biggest downside risk is a second consecutive guidance cut that pushes the stock back toward $267-275. It is a reasonable buy for patient, quality-oriented investors with a 12-18 month horizon who can tolerate another quarter of weak margin optics, and a poor buy for anyone seeking near-term momentum or a high-conviction catalyst.

SYK is structurally a long-term holding, not a short-term trade. It is a mature, large-cap franchise ($134.3 billion market cap, 56,000 employees) with a 0.774 beta that makes it roughly 23% less volatile than the market, a 0.96% dividend yield with a conservative 39.6% payout ratio, and earnings visibility supported by a tight consensus EPS band of $21.36-$22.51 (only ~5% spread). Those characteristics favor a minimum 12-18 month holding period that allows the Q4 2026 and 2027 guidance cycles to resolve the margin and procedure-volume question. Short-term traders face a difficult setup: the stock is down 17.08% over the trailing year and 11.07% YTD, the November spike from $310.55 to $339.65 has already given back ~8.8%, and the $339.65-352.25 resistance zone has rejected two rallies. The one-month gain of 9.95% versus SPY's -2.26% shows buyers stepping in near the $270-275 base, but that is a counter-trend rally within a damaged downtrend rather than a confirmed reversal — long-term investors can accumulate on weakness, while traders should wait for a decisive close above $352 before treating the trend as repaired.